In a prospective clinical trial, the relationship between the intraocular pressure-lowering efficacy of latanoprost 0.005% and the height of the ciliary body face exposed to the anterior chamber was assessed in untreated, latanoprost-naive patients with ocular hypertension or open-angle glaucoma. Fifty-four eyes (54 patients) were enrolled. The mean age of participants was 60.2 (±13.9) years. A radial, perpendicular ultrasound biomicroscopy image at the 6-o’clock position detailing the Schwalbe line, scleral spur, and iris insertion was obtained. The distance between these structures was measured and their relationship to the intraocular lowering pressure of latanoprost at 1, 2, 3, and 6 months was analyzed. The mean height of the trabecular meshwork was 0.72 (±0.1) mm and the mean height of exposed ciliary body face was 0.14 (±0.08) mm. The mean pretreatment intraocular pressure was 26.4 (±3.8) mm Hg. The mean pressure reduction from baseline was 7.1, 7.3, 7.8 and 7.7 mm Hg at 1, 2, 3 and 6 months, respectively. There was significant correlation between intraocular pressure lowering and the trabecular meshwork height at 1 month (P < 0.05) but not at 2, 3, or 6 months. There was no statistically significant correlation between intraocular pressure lowering and the height of exposed ciliary face. Although latanoprost lowers intraocular pressure by enhancing uveoscleral outflow, its efficacy is independent of the width of the ciliary body exposed to the anterior chamber.—Michael D. Wagoner